glp 1 drugs and thyroid cancer GLP-1 Medicines Risk Explained Glucagon-like peptide 1 receptor agonists
Description
Instead of increasing GLP-1 activity, it blocks or reduces it
Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
Vokinger KN, Nussli E, Dusetzina SB
MG: Supervision, Writing review & editing
Why dual agonism outperforms single-receptor activation Single GLP-1 agonists like semaglutide produce substantial weight loss, typically 10-15% body weight reduction over 6-12 months
[3] A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)
